We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Horizon Discovery Sign Worldwide Exclusive License to new Inventions from University of Torino
News

Horizon Discovery Sign Worldwide Exclusive License to new Inventions from University of Torino

Horizon Discovery Sign Worldwide Exclusive License to new Inventions from University of Torino
News

Horizon Discovery Sign Worldwide Exclusive License to new Inventions from University of Torino

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Horizon Discovery Sign Worldwide Exclusive License to new Inventions from University of Torino"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Horizon Discovery (Horizon) announced that it has entered into a world-wide exclusive patent licensing agreement with the, University of Torino relating to the novel use of human isogenic cell-lines in predicting the response of drugs targeted at the genetic make-up of individual cancer patient populations.

The discoveries that led to the invention were made by scientists at the Department of Oncological Sciences, University of Torino Medical School. The invention relates to the use of panels of precisely engineered isogenic human cell-lines that accurately model one or more genetic mutations seen in cancer patients.

The models have been shown to predict clinical outcomes of cancer patient populations to novel treatments targeted at specific genetic defects. Applications relating to modeling patient drug resistance mechanisms and patient stratification have been reduced to practice. The new inventions embodied in the licensed patent will underpin existing and new service and license offerings of Horizon.

Dr Chris Torrance, CEO of Horizon Discovery says “The key to generating such patient-relevant and predictive disease models is the precise targeting of defined endogenous genes using highly efficient homologous-recombination techniques such as GENESIS™; Horizon’s own gene-engineering platform. This new IP covers the use of endogenous gene-targeted human disease models generated via homologous recombination methodologies, in numerous aspects of targeted and personalized drug discovery; including clinical trial selection and the identification of drug combination therapies to overcome inherent or acquired genetic-based patient resistance. In future all of Horizon’s X-MAN™ products and screening services will be provided with an extended license to employ these new inventions”.

Under this agreement, Horizon will pay the University of Torino undisclosed fees and will assume the prosecution and sub-licensing control of the patent estate. The license came into effect on August 1st 2009.
Advertisement